search
Back to results

STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures (STEP)

Primary Purpose

Peripheral Arterial Disease

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Arterial closure to ensure hemostasis at femoral artery puncture points
Proglide® (Abbott)
Femoseal® (Terumo)
Arterial closure to ensure hemostasis at femoral artery puncture points
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Peripheral Arterial Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 18 years,
  • Patient with peripheral arterial disease
  • Endovascular examination or treatment compatible with a 5F to 7F sheath
  • Walking ability
  • Patient affiliated with a social security scheme
  • Patient's signed informed consent form

Exclusion Criteria:

  • Under-age patient
  • Patient of age, but under legal guardianship or care
  • Contraindication to endovascular treatment
  • Use of a 8F or greater sheath
  • Morbidity contraindicating same-day walking
  • History of ipsilateral open common femoral artery surgery
  • Stent at the puncture site
  • Radial or brachial puncture
  • Antegrade femoral puncture
  • Acute ischemia
  • Life expectancy of less than one month
  • Patient refusal to take part in the study
  • Participation in another therapeutic trial
  • Pregnant woman
  • Allergy to clopidogrel or aspirin

Sites / Locations

  • CHU Angers
  • CHU Brest
  • CH de Cholet
  • CHD La Roche-sur-Yon
  • CHU de Poitiers
  • CHU de Rennes

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Arterial closure device used is Proglide® (Abbott)

Arterial closure device used is Femoseal® (Terumo)

Arm Description

Outcomes

Primary Outcome Measures

Technical success defined as hemostasis at the puncture site without major complications.

Secondary Outcome Measures

Occurrence of major cardio-vascular events
Occurrence of major punctured femoral artery events during the perioperative period
Occurrence of minor punctured femoral artery events during the perioperative period
Walking ability
Time before restart of the ambulation measured in minutes from when the sheath of the introducer of the arterial closure system is removed and the moment when the patient is able to walk 100 meters without the recurrence of bleeding.
Quality of life evaluation (EQ-5D)
Cost-Outcome Ratio of patient care with FemoSeal® (St Jude) and Proglide® (Abbott)
The measure of effectiveness will be the utility obtained from the EQ-5D quality of life questionnaire

Full Information

First Posted
June 12, 2017
Last Updated
July 2, 2019
Sponsor
Nantes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03192033
Brief Title
STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures
Acronym
STEP
Official Title
STEP: Proglide® Versus Femoseal®: A Randomized Controlled Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
December 4, 2017 (Actual)
Primary Completion Date
June 25, 2019 (Actual)
Study Completion Date
June 25, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Over the past years, arterial closure systems have tended to replace manual compression to ensure hemostasis at femoral artery puncture points. Arterial closure systems reduce hemostasis and patient immobilization times, thus enabling early resumption of walking. These devices have contributed extensively to the development of outpatient stays for cardiology, vascular and neuro-radiology procedures. However, main arterial closure devices use different technology to close the arterial puncture point. For some, hemostasis is achieved by sealing the arteriotomy between two discs (an inner and an outer). For others, they are designed to close puncture sites delivering a single monofilament polypropylene suture mediated by needles. The investigators hypothesis is based on a different efficacy between both arterial closure devices for peripheral arterial disease (PAD) patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A duplex scan guided retrograde femoral puncture is performed followed by the use of a closure arterial device to ensure hemostasis. Patients are randomly assigned to be closed by Proglide® (Abbott) versus Femoseal® (Terumo)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
233 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arterial closure device used is Proglide® (Abbott)
Arm Type
Other
Arm Title
Arterial closure device used is Femoseal® (Terumo)
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
Arterial closure to ensure hemostasis at femoral artery puncture points
Intervention Description
Arterial closure devices used: Proglide® (Abbott)
Intervention Type
Device
Intervention Name(s)
Proglide® (Abbott)
Intervention Description
Arterial closure device used: Proglide® (Abbott)
Intervention Type
Device
Intervention Name(s)
Femoseal® (Terumo)
Intervention Description
Arterial closure device used: Femoseal® (Terumo)
Intervention Type
Other
Intervention Name(s)
Arterial closure to ensure hemostasis at femoral artery puncture points
Intervention Description
Arterial closure device used: Femoseal® (Terumo)
Primary Outcome Measure Information:
Title
Technical success defined as hemostasis at the puncture site without major complications.
Time Frame
Hour 5
Secondary Outcome Measure Information:
Title
Occurrence of major cardio-vascular events
Time Frame
Month 1
Title
Occurrence of major punctured femoral artery events during the perioperative period
Time Frame
Hour 5
Title
Occurrence of minor punctured femoral artery events during the perioperative period
Time Frame
Hour 5
Title
Walking ability
Description
Time before restart of the ambulation measured in minutes from when the sheath of the introducer of the arterial closure system is removed and the moment when the patient is able to walk 100 meters without the recurrence of bleeding.
Time Frame
Hour 5
Title
Quality of life evaluation (EQ-5D)
Time Frame
Month 1
Title
Cost-Outcome Ratio of patient care with FemoSeal® (St Jude) and Proglide® (Abbott)
Description
The measure of effectiveness will be the utility obtained from the EQ-5D quality of life questionnaire
Time Frame
Month 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 years, Patient with peripheral arterial disease Endovascular examination or treatment compatible with a 5F to 7F sheath Walking ability Patient affiliated with a social security scheme Patient's signed informed consent form Exclusion Criteria: Under-age patient Patient of age, but under legal guardianship or care Contraindication to endovascular treatment Use of a 8F or greater sheath Morbidity contraindicating same-day walking History of ipsilateral open common femoral artery surgery Stent at the puncture site Radial or brachial puncture Antegrade femoral puncture Acute ischemia Life expectancy of less than one month Patient refusal to take part in the study Participation in another therapeutic trial Pregnant woman Allergy to clopidogrel or aspirin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philippe CHAILLOU, Doctor
Organizational Affiliation
Nantes University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
CHU Angers
City
Angers
Country
France
Facility Name
CHU Brest
City
Brest
Country
France
Facility Name
CH de Cholet
City
Cholet
Country
France
Facility Name
CHD La Roche-sur-Yon
City
La Roche-sur-Yon
Country
France
Facility Name
CHU de Poitiers
City
Poitiers
Country
France
Facility Name
CHU de Rennes
City
Rennes
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34386892
Citation
Goueffic Y, Picquet J, Schneider F, Kaladji A, Marret O, Muller L, Guyomarc'h B, Riche VP, Chaillou P, Guillou M, Nasr B. A Randomized Trial Comparing Polymer Versus Suture-Based Vascular Closure Devices for Arterial Closure Following Lower-Limb Arterial Endovascular Revascularization. Cardiovasc Intervent Radiol. 2021 Dec;44(12):1883-1892. doi: 10.1007/s00270-021-02940-z. Epub 2021 Aug 13.
Results Reference
derived

Learn more about this trial

STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures

We'll reach out to this number within 24 hrs